Explore more price target data and ratings for Agios Pharmaceuticals, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Agios Pharmaceuticals, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems…
Shares of Agios Pharmaceuticals (AGIO) fell more than 4% in early trading, after the biotech firm said it will discontinue development of its therapy for sickle cell disease after a Phase 2 trial showed disappointing results.Why Is Agios Discontinuing Tebapivat For Sickle Cell Disease?On Monday, Ag…
Shares of Agios Pharmaceuticals (AGIO) jumped more than 14% to their highest level in over seven months after the company secured a key regulatory milestone for its sickle cell disease therapy, while upbeat Wall Street expectations ahead of second-quarter earnings further boosted investor sentiment…
Explore more price target data and ratings for Agios Pharmaceuticals, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Agios Pharmaceuticals, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems…
CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. NASDAQ:AGIO, a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its sup…
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. NASDAQ:AGIO, a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday…
